Disease specific status and generic health status improvements from TAVR and SAVR
Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to… [ Get More Details ]
Survival rates of SAS patients ages 80+ with and without SAVR
Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.
[ Get More Details ]
Cost-effectiveness of TAVR in sSAS patients
Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY… [ Get More Details ]